Neuropathic Pain Research Reagents

Neuropathic pain arises from lesions or diseases of the somatosensory nervous system, affecting up to 10% of the general population. Key mechanisms involve peripheral and central sensitization through voltage-gated sodium channels (Nav1.7/1.8), TRP channels, CGRP signaling, and neuroinflammatory mediators. The success of CGRP-targeting monoclonal antibodies for migraine has validated neuropeptide pathways as therapeutic targets for pain research.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Neuropathic Pain Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key neuropathic pain research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

CGRP (Calcitonin Gene-Related Peptide) — CGRP is a potent vasodilator and pain mediator released from trigeminal sensory neurons. Anti-CGRP antibodies (erenumab, galcanezumab class) have validated this target clinically. Research-grade anti-CGRP antibodies and recombinant CGRP proteins support receptor binding and signaling studies.
→ Browse CGRP antibodies & proteins

NGF (Nerve Growth Factor) — NGF-TrkA signaling sensitizes nociceptors and promotes chronic pain states. Anti-NGF antibodies (tanezumab class) and recombinant NGF proteins enable pain pathway research and analgesic drug mechanism-of-action studies.
→ Browse NGF antibodies & proteins

TRPV1 — TRPV1 (vanilloid receptor 1) is a polymodal nociceptor integrating thermal, chemical, and inflammatory pain signals. Anti-TRPV1 antibodies support expression profiling in dorsal root ganglia and functional antagonist screening.
→ Browse TRPV1 antibodies

Substance P (TAC1) — Substance P is a neuropeptide transmitter in pain signaling via NK1 receptors in the spinal dorsal horn. Anti-substance P antibodies and recombinant proteins support nociceptive pathway mapping and NK1 antagonist research.
→ Browse Substance P antibodies & proteins

References

1. Colloca L, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. DOI

2. Edvinsson L, et al. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350. DOI

3. Mantyh PW, et al. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189-204. DOI

4. Basbaum AI, et al. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267-284. DOI